Cargando…

Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study

BACKGROUND: Drug-related toxicity has been one of the main causes of antiretroviral treatment discontinuation. However, its determinants are not fully understood. Aim of this study was to investigate predictors of first-line antiretroviral therapy discontinuation due to adverse events and their evol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prosperi, Mattia CF, Fabbiani, Massimiliano, Fanti, Iuri, Zaccarelli, Mauro, Colafigli, Manuela, Mondi, Annalisa, D’Avino, Alessandro, Borghetti, Alberto, Cauda, Roberto, Di Giambenedetto, Simona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519703/ https://www.ncbi.nlm.nih.gov/pubmed/23145925 http://dx.doi.org/10.1186/1471-2334-12-296

Ejemplares similares

Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients
por: Fabbiani, Massimiliano, et al.
Publicado: (2014)

Single-tablet regimen is associated with reduced efavirenz withdrawal in antiretroviral naïve or switching for simplification HIV-infected patients
por: Fabbiani, M, et al.
Publicado: (2012)

Liver fibrosis is associated with cognitive impairment in HIV-positive patients
por: Ciccarelli, Nicoletta, et al.
Publicado: (2014)

Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk
por: D'Avino, Alessandro, et al.
Publicado: (2014)

Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance
por: Baldonero, Eleonora, et al.
Publicado: (2013)

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre
por: Borghetti, Alberto, et al.
Publicado: (2014)

Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping
por: Prosperi, Mattia CF, et al.
Publicado: (2010)

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study
por: Latini, Alessandra, et al.
Publicado: (2016)

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis
por: Zaccarelli, Mauro, et al.
Publicado: (2014)

Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience
por: Colafigli, Manuela, et al.
Publicado: (2019)

The Threshold Bootstrap Clustering: A New Approach to Find Families or Transmission Clusters within Molecular Quasispecies
por: Prosperi, Mattia C. F., et al.
Publicado: (2010)

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial
por: Fabbiani, Massimiliano, et al.
Publicado: (2014)

No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy
por: Lombardi, Francesca, et al.
Publicado: (2021)

A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen
por: Prosperi, Mattia CF, et al.
Publicado: (2011)

Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study
por: Lombardi, Francesca, et al.
Publicado: (2023)

Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice
por: Borghetti, Alberto, et al.
Publicado: (2021)

The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition
por: Delle Donne, Valentina, et al.
Publicado: (2020)

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
por: Ciccullo, Arturo, et al.
Publicado: (2019)

Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study
por: Lombardi, Francesca, et al.
Publicado: (2016)

Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study
por: Cusato, Jessica, et al.
Publicado: (2022)

Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak
por: Lombardi, Francesca, et al.
Publicado: (2021)

Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
por: Restelli, Umberto, et al.
Publicado: (2017)

Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
por: Restelli, Umberto, et al.
Publicado: (2017)

Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients
por: Fabbiani, Massimiliano, et al.
Publicado: (2023)

Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study
por: Focà, Emanuele, et al.
Publicado: (2016)

Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype
por: Salvo, Pierluigi Francesco, et al.
Publicado: (2023)

Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA
por: Bianco, Claudia, et al.
Publicado: (2014)

The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case–control study
por: De Luca, Andrea, et al.
Publicado: (2013)

A novel methodology for large-scale phylogeny partition
por: Prosperi, Mattia C.F., et al.
Publicado: (2011)

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial
por: Rossetti, Barbara, et al.
Publicado: (2017)

Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line
por: Ciccullo, Arturo, et al.
Publicado: (2020)

Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received
por: Motta, Davide, et al.
Publicado: (2012)

Combining Epidemiological and Genetic Networks Signifies the Importance of Early Treatment in HIV-1 Transmission
por: Zarrabi, Narges, et al.
Publicado: (2012)

Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models
por: Prosperi, Mattia C. F., et al.
Publicado: (2010)

Correction: Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models
por: Prosperi, Mattia C. F., et al.
Publicado: (2011)

Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy
por: Jose, Sophie, et al.
Publicado: (2014)

First-line antiretroviral drug discontinuations in children
por: Fortuin-de Smidt, Melony, et al.
Publicado: (2017)

Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016
por: Bellino, S., et al.
Publicado: (2019)

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
por: Bianco, Claudia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ud3qavahr7i0vaq55hq753p49p